AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

With multiple large M&A deals already announced in January, CEOs of major med-tech companies outlining acquisition plans for 2025 and declining interest rates, the stage is set for a significantly ...

What a difference 60 weeks can make. That’s the lesson Akero Therapeutics Inc. shared with the rollout of what executives called “unprecedented” data from the phase IIb Symmetry trial testing ...

Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (NYSE: ABBV) wasn't one of them. The ...

Northland Power Inc. ("Northland") (TSX: NPI) announces it will release its 2024 fourth quarter operating and financial results after markets close on Wednesday ...

AbbVie Inc. closed 14.67% below its 52-week high of $207.32, which the company achieved on October 31st.

Learn more about the presidencies of stakes created in Cedar City and Highland, Utah; Kasapa, Democratic Republic of the ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.

The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ...

Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $227 from $220 and keeps an Overweight rating on ...